The DEI Mandate: What’s on the Horizon and What Updates are Needed for IRB and Recruitment Processes (Part 1 of 2)

Are you prepared to meet the Food and Drug Administration’s (FDA ) upcoming requirements on Diversity Action Plans for clinical trials? Learn what the new guidance outlines, including the format, content, timing, and process of implementing Diversity Action Plans into clinical trials. Incorporating comprehensive Diversity, Equity, and Inclusion (DEI) strategies into trial planning, design, and execution enhances representation, optimizes health equity, and strengthens site selection, recruitment, and ethical review.

Join our informational webinar to get ahead of the curve on improving enrollment of participants from underrepresented populations in your studies.

Key Topics:

• Overview of the FDA’s guidance on Diversity Action Plans for clinical trials.
• The impact of the Diverse and Equitable Participation in Clinical Trials (DEPICT) Act passed by U.S. Congress.
• Actionable recommendations for sites, sponsors, and CROs to improve DEI implementation.